Oncolytics Biotech (TSE:ONC) has released an update.
Oncolyics Biotech has announced a positive outcome from its FDA Type C meeting, paving the way for a pivotal trial for pelareorep in HR+/HER2- metastatic breast cancer. The FDA has endorsed the use of progression-free survival as the main goal of the upcoming study. The company is set to release overall survival data from the BRACELET-1 trial in the second half of 2024, which is anticipated to enhance the drug’s profile for potential registration.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
